ROSEN Counsel Encourages Corcept Therapeutics

Top-ranked global investor law firm advises Corcept investors to take action.

Mar. 30, 2026 at 3:07am

Got story updates? Submit your updates here. ›

ROSEN, a global investor rights law firm, is encouraging investors of Corcept Therapeutics Incorporated to take action regarding potential securities claims against the company. The firm believes Corcept may have issued materially misleading business information to the investing public.

Why it matters

Corcept Therapeutics is a pharmaceutical company focused on developing drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. Any potential securities fraud or misleading information from the company could impact investor confidence and the stock price.

The details

ROSEN's investigation centers around whether Corcept Therapeutics made false and/or misleading statements and/or failed to disclose information pertinent to investors. The firm is evaluating potential claims on behalf of Corcept investors and encouraging them to contact the firm to discuss their options.

  • The investigation was announced on March 29, 2026.

The players

ROSEN

A global investor rights law firm that specializes in representing investors in securities fraud class actions and shareholder derivative litigation.

Corcept Therapeutics Incorporated

A pharmaceutical company focused on developing drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage Corcept investors to contact us to discuss their legal rights and options.”

— Laurence Rosen, Managing Partner, ROSEN Law Firm

What’s next

ROSEN is encouraging Corcept investors to contact the firm to discuss their legal rights and options regarding the potential securities claims.

The takeaway

This investigation highlights the importance of transparency and accurate disclosure from pharmaceutical companies, as any potential misconduct can significantly impact investor confidence and stock performance.